NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Piper Sandler Companies (NYSE: PIPR), a leading investment bank, and BC Partners Credit, the $8 billion credit arm of international investment firm BC ...
NEW YORK - Piper Sandler Companies (NYSE: PIPR), a prominent investment bank, and BC Partners Credit have announced a strategic alliance aimed at enhancing debt capital market access for financial ...
On Monday, Piper Sandler showed a positive outlook for shares of USCB Financial Holdings (NASDAQ: USCB), shifting its rating from Neutral to Overweight and boosting the price target to $20.00 from ...
In a report released today, Peter Keith from Piper Sandler maintained a Hold rating on Sleep Number (SNBR – Research Report), with a price target of $12.00. The company’s shares closed ...
Piper Sandler Companies (NYSE:PIPR), a leading investment bank and institutional securities firm, has demonstrated resilience and strategic growth in a dynamic financial landscape. The company's ...
On Wednesday, Piper Sandler adjusted its price target for Exelixis (NASDAQ:EXEL), increasing it to $36.00 from the previous $33.00 while maintaining an Overweight rating on the stock. The revision ...
On Wednesday, Piper Sandler reaffirmed its Overweight rating on shares of e.l.f. Beauty (NYSE: NYSE:ELF), with a consistent price target of $162.00. The firm's stance comes ahead of the company's ...
On Wednesday, Piper Sandler adjusted its outlook on Olin Corporation (NYSE: NYSE:OLN) shares, reducing the price target to $51 from the previous target of $57 while maintaining an Overweight ...
On Wednesday, Biogen (NASDAQ:BIIB) stock received a boost from Piper Sandler, with the firm raising its price target on the stock to $315 from $307. The investment firm maintained its Overweight ...
On Monday, Piper Sandler maintained an Overweight rating on shares of Yeti Holdings Inc. (NYSE:NYSE:YETI), with a steady price target of $55.00. The firm expressed confidence in the company's ...
On Tuesday, Piper Sandler maintained its optimistic stance on shares of Zura Bio Ltd. (NASDAQ: ZURA), reiterating an Overweight rating with a $26.00 price target. The firm's confidence in Zura Bio ...
In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), with a price target of $21.00. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback